Collateral Damage: IgA Nephropathy Complicating Long-Term Certolizumab Pegol Use in Crohn's Disease (ACG 2026) - Aug 29, 2026 - Abstract #P3590; Pres time: Oct 12, 2026; 10:30 AM - 04:15 PM; Location: Exhibit Halls A - D (Level 3); "Case Description/ A 36-year-old male with CD diagnosed in 2010 (Paris classification: A2, L1, B2), underwent ileocolonic resection and was started on certolizumab pegol in 2011 after failing 5-aminosalicylic acid, 6-mercaptopurine, and infliximab therapy...Certolizumab pegol was stopped and CD treatment with vedolizumab was started. Treatment with corticosteroids, mycophenolate, losartan, and atrasentan was initiated...Targeted budesonide was not a treatment option in this case given prior bowel resection, which emphasizes a treatment consideration unique to CD patients. This case emphasizes the importance of routine renal monitoring in patients on long-term anti-TNF therapy. Figure: Light microscopy (PAS stain) demonstrating mesangial hypercellularity Figure: Immunofluorescence microscopy demonstrating diffuse mesangial IgA deposits"
Crohn's disease • Gastroenterology • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammation • Inflammatory Bowel Disease • Nephrology • Renal Disease
|
|
Maria Antonia Espinosa MD 1; Khaled H.. Husain MD 2; Bhoowit Lerttiendamrong MD 3; You Sung Sang MD 4
|